Unveiling new Kv1.3 channel blockers from scorpion venom: Characterization of Meuk7-3 and in silico design of its analogs for enhanced affinity and therapeutic potential
- PMID: 40533013
- DOI: 10.1016/j.ijbiomac.2025.145327
Unveiling new Kv1.3 channel blockers from scorpion venom: Characterization of Meuk7-3 and in silico design of its analogs for enhanced affinity and therapeutic potential
Abstract
Kv1.3 channels are associated with autoimmune and neuroinflammatory diseases. Scorpion venom is an excellent source of inhibitors for Kv1.3. Kv1.3, a pivotal voltage-gated potassium channel, has emerged as a critical therapeutic target for combating autoimmune and neuroinflammatory diseases, including multiple sclerosis and rheumatoid arthritis. Some studies have tried to discover highly selective toxins targeting Kv1.3 channels, but it is still challenging. Here, we present a groundbreaking discovery of a potent peptide potassium channel blocker, Meuk7-3, derived from the venom of the scorpion, Mesobuthus crucittii. While similar to other Kv1.3 blockers, Meuk7-3's Lys19 residue may enhance its affinity for the channel. So, we redesigned the Meuk7-3 and generated three analogous, Meuk7-3 A, Meuk7-3B, and Meuk7-3C, to improve its drug-like properties and affinity to Kv1.3. Interaction evaluation with Kv1.3 revealed that Meuk7-3 and all its designed analogous could of Kv1.3's pore through the interaction of Lys19 of the peptide with Tyr447, Tyr797, Tyr1147, and Tyr1497, critical residues located at the channel pore of Kv1.3.However, the stability of the interaction of designed peptides with Kv1.3 was more than Meuk7-3. Binding affinity analysis revealed that all designed peptides had a better binding affinity to Kv1.3 than Meuk7-3. Among the three analogous, Meuk7-3 A was found to have better drug-like properties and interaction situations, including binding energy and affinity to Kv1.3, compared to Meuk-3 native. These findings provide new data for designing highly effective Kv1.3 inhibitors by computational tools for treating autoimmune and inflammatory diseases, although experimental testing is necessary to validate them.
Keywords: Autoimmune diseases; Potassium channel blocker; Scorpion venom peptide.
Copyright © 2025 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Cvill6 and Cvill7: Potent and Selective Peptide Blockers of Kv1.2 Ion Channel Isolated from Mexican Scorpion Centruroides villegasi.Toxins (Basel). 2025 Jun 4;17(6):279. doi: 10.3390/toxins17060279. Toxins (Basel). 2025. PMID: 40559857 Free PMC article.
-
The Black Book of Psychotropic Dosing and Monitoring.Psychopharmacol Bull. 2024 Jul 8;54(3):8-59. Psychopharmacol Bull. 2024. PMID: 38993656 Free PMC article. Review.
-
Mechanisms Underlying the Inhibition of KV1.3 Channel by Scorpion Toxin ImKTX58.Mol Pharmacol. 2022 Sep;102(3):150-160. doi: 10.1124/molpharm.121.000480. Epub 2022 Jun 28. Mol Pharmacol. 2022. PMID: 35764383
-
Home treatment for mental health problems: a systematic review.Health Technol Assess. 2001;5(15):1-139. doi: 10.3310/hta5150. Health Technol Assess. 2001. PMID: 11532236
-
Synthetic ShK-like Peptide from the Jellyfish Nemopilema nomurai Has Human Voltage-Gated Potassium-Channel-Blocking Activity.Mar Drugs. 2024 May 13;22(5):217. doi: 10.3390/md22050217. Mar Drugs. 2024. PMID: 38786608 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources